Cargando…

A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia

Detalles Bibliográficos
Autores principales:	Uy, G L, Rettig, M P, Stone, R M, Konopleva, M Y, Andreeff, M, McFarland, K, Shannon, W, Fletcher, T R, Reineck, T, Eades, W, Stockerl-Goldstein, K, Abboud, C N, Jacoby, M A, Westervelt, P, DiPersio, J F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380905/ https://www.ncbi.nlm.nih.gov/pubmed/28282031 http://dx.doi.org/10.1038/bcj.2017.21

Ejemplares similares

Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor
por: Fadini, Gian Paolo, et al.
Publicado: (2015)

Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning in allogeneic stem cell transplantation
por: Konopleva, Marina, et al.
Publicado: (2015)

Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10‐day decitabine regimen
por: Ali, Alaa M., et al.
Publicado: (2017)

Machine learning–based scoring models to predict hematopoietic stem cell mobilization in allogeneic donors
por: Xiang, Jingyu, et al.
Publicado: (2022)

Plerixafor
por: Slater, Susan
Publicado: (2012)

A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome
por: McDermott, David H., et al.
Publicado: (2023)

Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition
por: Sison, Edward Allan R., et al.
Publicado: (2014)

Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation
por: Slade, Michael, et al.
Publicado: (2016)

Plerixafor for autologous CD34(+) cell mobilization
por: Salman, Huda, et al.
Publicado: (2011)

Targeting CXCR4 in AML and ALL
por: Cancilla, Daniel, et al.
Publicado: (2020)

Mobilized peripheral blood: an updated perspective
por: Karpova, Darja, et al.
Publicado: (2019)

A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML)
por: Uy, Geoffrey, et al.
Publicado: (2014)

Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide
por: Crees, Zachary D., et al.
Publicado: (2023)

Successful mobilization using a combination of plerixafor and G-CSF in pediatric patients who failed previous chemomobilization with G-CSF alone and possible complications of the treatment
por: Hong, Kyung Taek, et al.
Publicado: (2012)

Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor
por: Crees, Zachary D., et al.
Publicado: (2023)

Bone marrow necrosis in a patient with advanced Hodgkin's lymphoma after G-CSF and Plerixafor treatment during harvesting for autologous bone marrow transplantation: is it possible?
por: Khoshnaw, Najmaddin, et al.
Publicado: (2021)

P932: ON-DEMAND PLERIXAFOR WITH CYCLOPHOSPHAMIDE AND G-CSF FOR HEMATOPOIETIC STEM-CELL MOBILIZATION IN MULTIPLE MYELOMA PATIENTS: FINAL RESULTS OF THE MOZOBL06877 STUDY
por: Mina, R., et al.
Publicado: (2022)

P1316: INCREASED EFFICACY OF INTERMEDIATE-DOSE ARAC+G-CSF COMPARED TO CY+G-CSF AND PLERIXAFOR+G-CSF AS A STEM CELL MOBILIZATION REGIMEN IN POOR MOBILIZERS WITH HEMATOLOGICAL MALIGNANCIES
por: Elkhova, Svetlana, et al.
Publicado: (2023)

Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial
por: Crees, Zachary D., et al.
Publicado: (2023)

Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine
por: Tabe, Yoko, et al.
Publicado: (2018)

Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: High effectiveness, low toxicity, and affordable cost
por: Milone, Giuseppe, et al.
Publicado: (2020)

Suicide genes: monitoring cells in patients with a safety switch
por: Eissenberg, Linda G., et al.
Publicado: (2014)

Efficacy of Afternoon Plerixafor Administration for Stem Cell Mobilization
por: El Rahi, Cynthia, et al.
Publicado: (2018)

Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia
por: Barnell, Erica K., et al.
Publicado: (2021)

Insights into the role of the JAK/STAT signaling pathway in graft-versus-host disease
por: Abboud, Ramzi, et al.
Publicado: (2020)

Decitabine salvage for TP53-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy
por: Ferraro, Francesca, et al.
Publicado: (2022)

Plerixafor use for peripheral blood stem cell mobilization in Korea
por: Kim, Seok Jin, et al.
Publicado: (2013)

Addition of plerixafor in poorly mobilized allogeneic stem cell donors
por: Zhuang, Lefan, et al.
Publicado: (2022)

Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update
por: Bilgin, Yavuz M
Publicado: (2021)

Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy
por: Uy, Geoffrey L., et al.
Publicado: (2016)

Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia
por: Roboz, Gail J., et al.
Publicado: (2018)

How to Screen for Monoclonal Gammopathy in Patients With a Suspected Amyloidosis
por: Rubinstein, Samuel M., et al.
Publicado: (2021)

P1343: TRANSPLANT OUTCOMES OF LYMPHOMA PATIENTS UNDERGOING STEM CELL MOBILIZATION WITH PLERIXAFOR
por: Gunes, A. K., et al.
Publicado: (2022)

Case Study in Refractory Non-Hodgkin's Lymphoma: Successful Treatment with Plerixafor
por: Azim, Hamdy Abdel, et al.
Publicado: (2011)

Plerixafor in the Treatment of Stem Cell Mobilization Failure; First Experience in Iran
por: Mehdizadeh, Mahshid, et al.
Publicado: (2013)

Use of Plerixafor to Mobilize a Healthy Donor Infected with Influenza A
por: Yeral, Mahmut, et al.
Publicado: (2018)

Plerixafor as a salvage mobilization strategy for haploidentical peripheral blood allogeneic stem cell transplantation
por: Nadeau, Michelle, et al.
Publicado: (2015)

The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor
por: Karpova, D, et al.
Publicado: (2013)

Beyond adhesion: emerging roles for integrins in control of the tumor microenvironment
por: Longmate, Whitney, et al.
Publicado: (2017)

P2 3-year observation study of Plerixafor use in New Zealand
por: Swinn, Tim, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tedps5r93m9mb3ih3mpg11crk8